Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy

Autologous CD19 CAR-T-cell therapy can induce curative remissions in relapsed or refractory B-cell lymphoma, yet manufacturing lead times and treatment-related toxicities still confine its use largely to specialized centers (1). CD20×CD3 bispecific antibodies have broadened availability of T-cell-engaging therapies, but relapse remains common, and many patients enter later lines of therapy with compromised marrow reserve, which may limit both efficacy and tolerability (2). Despite these advances, an unmet need persists for cellular immunotherapy that can be manufactured at scale, delivered on demand, and administered with a predictable safety profile.

Strati and colleagues report the first-in-human phase 1 evaluation of FT516, an induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell product engineered to express a high-affinity, non-cleavable CD16 (FcγRIIIa) to enhance antibody-dependent cellular cytotoxicity (ADCC) in combination with an anti-CD20 monoclonal antibody (3). In this multicenter study, 55 patients with relapsed or refractory CD20-positive B-cell lymphoma received lymphodepletion with fludarabine plus cyclophosphamide or bendamustine, followed by an anti-CD20 antibody (rituximab or obinutuzumab) and FT516 infusions on days 1, 8, and 15; subcutaneous IL-2 was administered after each infusion. The maximum tested dose, 9×10⁸ cells per infusion for three infusions, was tolerated and selected as the recommended phase 2 dose, and no dose-limiting toxicities were reported (3).

The safety profile is notable, not for the absence of adverse events, but for a pattern that differs from what is typically observed with T cell-based immunotherapies. Cytokine release syndrome occurred in one patient (2%) and was grade 1, and no neurotoxicity was observed (3). By contrast, the predominant grade 3 or higher events were neutropenia (84%), thrombocytopenia (36%), and anemia (27%) (3). Although the low frequency of inflammatory toxicities is encouraging, the high rate of severe neutropenia remains clinically important and highlights that hematologic toxicity was still a major treatment-related burden in this regimen. These hematologic toxicities should not be attributed to FT516 alone, because the regimen combined lymphodepletion, anti-CD20 antibody therapy, IL-2 administration, and the cell product. The median duration of grade 3 or higher neutropenia was 10 days, suggesting that conditioning likely contributed substantially, but a contribution from FT516 itself cannot be excluded. Taken together with the low incidence of cytokine release syndrome and absence of neurotoxicity, the observed cytopenia profile is best interpreted in the context of the full regimen rather than conditioning alone. Overall, these findings support continued evaluation of this platform while underscoring the need to better define the relative contribution of each treatment component to hematologic toxicity.

Because this phase 1 study was designed primarily for safety evaluation and dose selection, the efficacy findings remain exploratory. Objective responses were observed in 32 (58%) of 55 individuals (3). In indolent lymphoma, all 12 patients responded, including 11 (92%) complete responses; in aggressive large B-cell lymphoma, objective responses were observed in 18 (49%) of 37 patients (3). These results are encouraging, particularly the depth of response in indolent disease, but durability remains exploratory in the absence of a comparator arm and with limited cohort sizes. Taken together, these findings support further phase 2 development rather than definitive conclusions about long-term disease control.

FT516 also exemplifies a rational engineering strategy. ADAM17-mediated CD16 shedding upon NK-cell activation is a well-recognized constraint to durable ADCC effect, as loss of surface CD16 attenuates Fc receptor signaling and diminishes cytotoxic function (4,5). FT516 addresses this limitation by incorporating a non-cleavable CD16 variant into a renewable iPSC-derived NK-cell product, preserving receptor expression while mitigating two long-standing hurdles in NK-cell therapy: donor dependence and inter-batch dose variability. This approach is supported by preclinical data showing enhanced antitumor activity of pluripotent stem cell-derived NK cells expressing a high-affinity, non-cleavable CD16a (5), and is consistent with early clinical experience from iPSC-derived CD19 CAR-NK products generated by the same platform (6). More broadly, iPSC-derived NK-cell therapies occupy a distinct position within the NK-cell landscape. Compared with donor-derived or cord blood-derived NK-cell products, they offer clonal starting material, manufacturing consistency, cryopreservable multi-dose availability, and greater flexibility for multiplex genetic engineering (7,8).

At the same time, limited in vivo persistence remains a central challenge for NK-cell therapy. The weekly multi-dose schedule and IL-2 support used in this study might help sustain antitumor activity, but future trials should report the duration of cell detectability in blood more systematically and, when feasible, include pharmacokinetic and prespecified tissue-based assessments (3). Such data will be essential for interpreting whether response durability is driven by repeated dosing, biologic persistence, or favorable disease biology. The iPSC platform is especially attractive in this regard because clonal engineering before large-scale manufacturing can support additional modifications beyond stabilized CD16, including CAR incorporation, cytokine support modules, and strategies to improve resistance to tumor microenvironment-mediated immunosuppression (6-9).

Clearer delineation of FT516’s clinical positioning relative to CD20×CD3 bispecific antibodies and CD19 CAR-T/NK cells, particularly in settings that prioritize rapid, on-demand treatment and outpatient delivery, will strengthen the rationale for phase 2 development. CD20×CD3 bispecific antibodies, including glofitamab and epcoritamab, have established a high benchmark for outpatient delivery and antitumor activity in relapsed or refractory large B-cell lymphoma (2,10). CAR-T cells remain the preferred option when curative intent and patient fitness permit. FT516 is therefore unlikely to replace CAR-T-cell therapy; rather, it may be most useful for patients who need rapid, on-demand treatment, for those in whom individualized CAR-T manufacture is less feasible, and in settings that prioritize broader access, outpatient delivery, or lower rates of inflammatory toxicity. In this sense, FT516 may be positioned as a complementary option within treatment sequencing rather than as a replacement for CAR-T. If larger studies confirm durable remissions in indolent lymphoma and clinically meaningful activity in aggressive disease, FT516 could define a complementary class of cellular therapeutics with drug-like manufacturing and distribution but retention of the biological potency of cell-based immunotherapy. Published data from this platform and related allogeneic CAR-NK studies also suggest that CAR incorporation through additional genetic engineering can preserve a favorable safety profile while improving efficacy, supporting a stepwise progression toward more potent off-the-shelf NK-cell therapies (6,11,12).

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Cancer Research. The article has undergone external peer review.

Peer Review File: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1-0358/prf

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-1-0358/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Crochet G, André M, Bernard W. Chimeric antigen receptor T-cell therapy in aggressive lymphomas. Curr Opin Oncol 2025;37:433-40. [Crossref] [PubMed]
2. Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica 2025;110:1483-99. [Crossref] [PubMed]
3. Strati P, Castro J, Goodman A, et al. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol 2025;12:e505-15. [Crossref] [PubMed]
4. Wang K, Wang L, Wang Y, et al. Reprogramming natural killer cells for cancer therapy. Mol Ther 2024;32:2835-55. [Crossref] [PubMed]
5. Zhu H, Blum RH, Bjordahl R, et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood 2020;135:399-410. [Crossref] [PubMed]
6. Ghobadi A, Bachanova V, Patel K, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 2025;405:127-36. [Crossref] [PubMed]
7. Sun J, Elliott M, Souza-Fonseca-Guimaraes F. Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy. Clin Transl Immunology 2025;14:e70045. [Crossref] [PubMed]
8. Wei X, Su C, Liu Y, et al. IPSC derived NK cells for immunotherapy and therapeutic perspective Mol Med Rep 2025;32:222. (Review). [Crossref] [PubMed]
9. Shah Z, Tian L, Caligiuri MA, et al. Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy. Cell Stem Cell 2026;33:184-201. [Crossref] [PubMed]
10. Nizamuddin IA, Bartlett NL. Bispecific antibodies in follicular lymphoma. Haematologica 2025;110:1472-82. [PubMed]
11. Biederstädt A, Bassermann F, Hecker JS. Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis. Front Immunol 2025;16:1585556. [Crossref] [PubMed]
12. Lei W, Liu H, Deng W, et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer 2025;6:786-800. [Crossref] [PubMed]